Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience

BACKGROUND: Chemotherapy plus targeted therapy is the established treatment for human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer (BC). Limited data regarding the safety and activity of the combination of eribulin and trastuzumab (E/T) in pretreated HER2-positive advanced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Tumori
Main Authors: Lutrino, Eufemia S., Orlando, Laura, Febbraro, Antonio, Giampaglia, Marianna, Zamagni, Claudio, Schiavone, Paola, Scavelli, Claudio, Dima, Gianluca, Fedele, Palma, Giordano, Guido, Bilancia, Domenico, Quaranta, Anna Maria, Rubino, Daniela, Filippelli, Gianfranco, Fontanella, Caterina, Caliolo, Chiara, Marino, Antonella, Calvani, Nicola, Ferrara, Pasqualinda, Cinieri, Saverio
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2019
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7372580/
https://ncbi.nlm.nih.gov/pubmed/31847742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300891619887225
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados